Cell-Free DNA Analysis Distinguishes Recurrent From Primary Breast Cancer
Kumamoto University researchers have developed a blood test that analyzes nucleosome structures in cell-free DNA to detect breast cancer recurrence.
Category: Breast
Breast
Latest
Breast
Latest
Liquid Biopsy Predicts Immunotherapy Response in Breast Cancer, Study Shows
Researchers at Vanderbilt-Ingram Cancer Center report that RNA sequencing of blood samples can predict immunotherapy response in high-risk breast cancer patients.
Breast
Latest
New AI Test Estimates Individualized Chemotherapy Benefit in Breast Cancer Patients
Using causal artificial intelligence and digital pathology, the test moves beyond population-level averages to predict patient-specific chemotherapy outcomes.
PreciseDx Presents Validation Data for AI Breast Cancer Recurrence Test
Three abstracts showcase PreciseBreast’s ability to predict recurrence risk in early-stage invasive breast cancer using digital pathology.
Read More
CTC Counts Show Value in Guiding Metastatic Breast Cancer Treatment Decisions
Researchers found that circulating tumor cell counts stratified patients by disease aggressiveness and were associated with differing outcomes following endocrine versus combination therapy.
Read More
Roche Gains FDA Approval for Expanded HER2 Diagnostic Test Indications
The test can now be used to identify HER2-positive metastatic breast cancer patients that could be eligible for Enhertu.
Read More
Test Validated to Predict Recurrence Risk and Radiation Therapy Benefit in Breast Cancer
A blinded validation in more than 400 women shows the test provides clearer guidance on recurrence risk and radiation therapy decisions.
Read More
Medicare Covers Ultrasensitive MRD Test for Breast Cancer Surveillance
Coverage applies to stage II and III breast cancer patients across three major subtypes for up to six years of recurrence monitoring.
Read More
YD Bio Expands US Access to Blood Test for Post‑Treatment Breast Cancer Monitoring
The research‑use‑only test for post‑treatment breast cancer monitoring is now available through the company’s affiliate EG Biomed US.
Read More
Biodesix Expands Bio-Rad Partnership for Droplet Digital PCR Assay Development
The agreement focuses on clinical validation of ESR1 mutation detection assay for advanced breast cancer testing using ddPCR technology.
Read More
Blood Test Achieves 85% Accuracy in Predicting Breast Cancer Immunotherapy Response
Researchers develop PIPscore using plasma proteomics to identify triple-negative breast cancer patients most likely to benefit from immunotherapy treatment.
Read More
Test Gains Medicare Coverage for Early-Stage Breast Cancer Recurrence Monitoring
Coverage marks a step in expanding access to ultra-sensitive molecular residual disease detection for breast cancer patients.
Read More
A Precision Oncology Approach Calls for Regular ESR1 Monitoring
Emerging liquid biopsy techniques enable sensitive, routine monitoring of ESR1 mutations in metastatic HR+ breast cancer.
Read More
PREDICT DNA and SCANDARE Study Results Unveiled
Personalis, Inc. unveiled promising new clinical data from the PREDICT DNA and SCANDARE studies at ASCO 2025.
Read More
MRD Detection Gets New Standard with Pathlight
SAGA Diagnostics has launched Pathlight, a groundbreaking multi-cancer blood test for ultra-sensitive detection of MRD.
Read More
Breast Cancer Index Test Data Reinforces Efficacy
Hologic and Biotheranostics unveiled new data showing that the Breast Cancer Index (BCI) test improves treatment decision-making.
Read More
Study IDs Two New Breast Cancer Genes in Black Women
A groundbreaking genetic study identified two novel breast cancer-linked genetic variants in Black South African women.
Read More
Ibex Breast Demonstrates High Accuracy, Efficiency in Study
A new peer-reviewed study confirms that Ibex Breast significantly enhances accuracy, speed, and efficiency of breast pathology evaluations.
Read More